U.S. markets closed

CryoLife, Inc. (CRY)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
18.31-0.53 (-2.81%)
At close: 1:00PM EST
18.31 -0.03 (-0.16%)
After hours: 01:01PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close18.84
Bid0.11 x 800
Ask21.05 x 1000
Day's Range17.60 - 18.50
52 Week Range17.60 - 32.34
Avg. Volume141,882
Market Cap720.125M
Beta (5Y Monthly)1.49
PE Ratio (TTM)435.95
EPS (TTM)0.04
Earnings DateFeb 09, 2022 - Feb 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateDec 09, 2015
1y Target Est33.44
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CRY

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CryoLife, Inc.
    CRY: Lowering target price to $20.00CRYOLIFE INC has an Investment Rating of HOLD; a target price of $20.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • PR Newswire

    CryoLife to Participate in the Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services Forum

    CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that members of management will host one-on-one meetings at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health & Services Forum on Thursday, November 18, 2021. Due to the format of this event no webcast will be available.

  • Zacks

    Wall Street Analysts Think CryoLife (CRY) Could Surge 51%: Read This Before Placing a Bet

    The mean of analysts' price targets for CryoLife (CRY) points to a 50.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

  • Motley Fool

    Cryolife Inc (CRY) Q3 2021 Earnings Call Transcript

    This is Pat Mackin CEO of CryoLife. The On-X product line growth was led by the On-X aortic valve revenue growth in North America, which grew 16% compared to 2019. Second, our cardiac tissue declined 10% in the third quarter compared to 2019, resulting from a backlog in review of donor and tissue charge to release this tissue, which, as you will recall, had been temporarily quarantine as a result of our previously discussed Tris issue.